Clairity CEO Jeff Luber to Present at BIO International Convention 2025, Highlighting FDA-Approved AI Breast Cancer Risk Prediction Platform

BOSTON--(BUSINESS WIRE)--Clairity, Inc., a company at the forefront of AI-powered human health solutions, has announced that its executive leadership team will attend and participate in the BIO International Convention 2025, set to take place from June 16-19, 2025, in Boston. CEO Jeff Luber will deliver the company update, providing insights into Clairity’s strategic direction and recent advancements. Additionally, Clairity executives will engage in one-on-one meetings with investors and potential partners to discuss key updates, particularly since the company secured FDA De Novo authorization for its innovative CLAIRITY BREAST platform. Those interested in scheduling a meeting can do so through the conference’s meeting portal or by contacting clairity@lavoiehealthscience.com. The BIO International Convention is the world’s premier biotechnology event, bringing together over 20,000 industry leaders from the global life sciences community. It serves as a critical forum for collaboration, innovation, and networking in the biotech sector. About CLAIRITY BREAST CLAIRITY BREAST, also known as Allix5, is a groundbreaking mammography-based AI risk prediction tool. This platform analyzes imaging data with pixel-level precision to identify individuals at high risk of developing breast cancer within the next five years. The AI model underlying CLAIRITY BREAST was extensively trained on millions of images and rigorously validated using over 77,000 mammograms from five distinct screening centers, including both hospital-based and free-standing facilities. These centers collectively serve a highly diverse patient population, ensuring the model’s broad applicability and reliability. For more details on the specific indications and uses, visit Clairity's website. About Clairity Founded in 2020 and based in Boston, Massachusetts, Clairity, Inc. is revolutionizing healthcare risk assessment through the integration of artificial intelligence and deep learning technologies. The company was established by Dr. Connie Lehman and is supported by prominent investors such as Santé Ventures, ACE Global Equity, and the Breast Cancer Research Foundation. Clairity’s platform excels at detecting subtle patterns in routine medical images that are imperceptible to the human eye, thereby significantly improving the accuracy of risk predictions. This advanced ability empowers clinicians and patients with actionable, personalized insights, facilitating a shift from reactive treatment to proactive prevention in healthcare. For more information, visit Clairity's website or connect with them on LinkedIn. More News From Clairity, Inc. Stay tuned for further announcements and news from Clairity, Inc. as they continue to push the boundaries of AI in healthcare.